Calando May 'Scale Back' RNAi Rx Development as Parent Firm Faces Cash Crunch

During a conference call held this week to discuss Arrowhead Research's fiscal first-quarter financial results, President and CEO Christopher Anzalone said that the company was in a position to stay afloat for at least the next nine months.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.